Copper levels in breast milk of women treated for Wilson's disease
Measures copper in breast milk of treated mothers with Wilson's disease.
Key facts
- Who runs it
- Fondation Ophtalmologique Adolphe de Rothschild
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Description of the Copper Concentration in Breast Milk in Women Treated for Wilson's Disease
- Status
- Recruiting
- People taking part
- 20 people, planned
- Started
- 11 May 2022
- Expected to end
- Mar 2027
- Type of study
- Interventional
- Treatments tested
- Patients with Wilson's disease declaring pregnancy,
- Record updated
- 1 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for pregnant women with Wilson's disease. It measures copper levels in their breast milk.
- Age
- 18 years or over
- Sex
- Women only
- Disease stage
- Wilson's disease confirmed by the Leipzig score. Pregnancy at any stage.
Main reasons for not taking part
- People who have had a liver transplant
- People not covered by a social security system
- People unable to give free and informed consent
- People under a legal protection measure
This trial only enrols pregnant participants. The registry sentence this rests on: * Pregnancy in progress whatever the term.
The registry criteria, word for word
Show all 10 criteriaShow less
Other criteria
- Criteria for inclusion :
- Patient aged 18 years or over
- Wilson's disease fulfilling the criteria for the Leipzig score
- Pregnancy in progress whatever the term
- Express consent to participate in the study
- Affiliate or beneficiary of a social security system; Criteria for non-inclusion :
- Liver transplant patient
- No affiliation to Social Security system
- VuInability to give free and informed consent
- Patient benefiting from a legal protection measure
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Wilson's disease is a rare genetic disease, affecting less than 1,500 people in France. The transmission is autosomal recessive linked to an anomaly of the ATP7B gene on chromosome.This gene codes for an ATPase-type transmembrane protein involved in the transport of copper through the cell plasma member.This gene codes for an ATPase-type transmembrane protein involved in the transport of copper through the cell plasma member. If there is no mutation, this ATPase incorporates copper into apo-ceruloplasmin to be released into the blood serum. The mutation of the ATP7B gene results in a defective biliary excretion of copper, leading to its accumulation in the liver, but also in other organs such as the eye or the brain. Advances in treatment have dramatically changed the prognosis for Wilson's disease, making the desire for pregnancy more confident.
Read full original descriptionShow less
The consensus is to maintain treatment during pregnancy, reducing the dosage to limit teratogenicity as well as the risk of fetal copper deficiency.The mammary gland is the primary site of copper metabolism in lactation, and ATPase 7B is the primary effector.
It has been shown in a mouse model of Wilson's disease (ATP7B - / - mouse) with treatment, that mothers accumulate copper in the liver but also in the mammary gland.
However, a recent study showed that the copper level in breast milk was normal in 18 Wilsonian patients treated with D-penicillamine, trientine salts or zinc salts, suggesting that breastfeeding is possible in these patients without risk to the development of the infants.The problem of breastfeeding newborns for patients with Wilson's disease is therefore associated with a risk of copper deficiency in the newborn due to insufficiently rich breast milk in copper due to drugs.
In addition, the passage into breast milk of treatments is not sufficiently known.
These factors make breastfeeding not currently recommended for Wilsonian mothers,However, many patients wish to breastfeed and some of them breastfeed their newborns despite the risk of breastfeeding
The group in the trial
- Patients with Wilson's disease declaring pregnancy,Other group
Patients with Wilson's disease declaring pregnancy.Followed in the reference, constituent, and competence centers for Wilson's disease and other rare copper-related diseases, spread over French national territory.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Description of the Copper Concentration in Breast Milk in Women Treated for Wilson's Disease
- Plain-language title
- Copper levels in breast milk of women treated for Wilson's diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 1 October 2026